Patents by Inventor Suneel K. Gupta
Suneel K. Gupta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9393192Abstract: Dosage forms and methods for providing a substantially ascending rate of release of paliperidone or risperidone are provided. The sustained release dosage forms provide therapeutically effective average steady-state plasma paliperidone or risperidone concentrations when administered once per day. This once-a-day dosing regimen results in only one peak plasma paliperidone or risperidone concentration occurrence in each 24 hour period. In addition, the peak plasma paliperidone or risperidone concentration occurs at a later time following dose administration and exhibits a lesser magnitude than the peak plasma paliperidone or risperidone concentration that occurs following administration of paliperidone or risperidone in an immediate-release dosage form.Type: GrantFiled: April 22, 2009Date of Patent: July 19, 2016Inventors: Nyomi V. Yam, Iran Reyes, Nipun Davar, Atul D. Ayer, Julie Lee, Sonya Seroff, Suneel K. Gupta, Gayatri Sathyan
-
Patent number: 9144549Abstract: Methods and devices for maintaining a desired therapeutic drug effect over a prolonged therapy period are provided. In particular, oral dosage forms that release drug within the gastrointestinal tract at an ascending release rate over an extended time period are provided. The dosage forms may additionally comprise an immediate-release dose of drug.Type: GrantFiled: March 13, 2013Date of Patent: September 29, 2015Assignee: ALZA CORPORATIONInventors: Suneel K. Gupta, Diane R Guinta, Carol A. Christopher, Samuel R. Saks, Lawrence G. Hamel
-
Patent number: 9029416Abstract: Methods and devices for maintaining a desired therapeutic drug effect over a prolonged therapy period are provided. In particular, oral dosage forms that release drug within the gastrointestinal tract at an ascending release rate over an extended time period are provided. The dosage forms may additionally comprise an immediate-release dose of drug.Type: GrantFiled: August 12, 2003Date of Patent: May 12, 2015Assignee: Alza CorporationInventors: Andrew C. Lam, Padmaja Shivanand, Atul D. Ayer, Zahedeh Hatamkhany, Suneel K. Gupta, Diane R. Guinta, Carol A. Christopher, Samuel R. Saks, Lawrence G. Hamel, Jeri D. Wright, Richard G. Weyers
-
Publication number: 20150125493Abstract: Methods and devices for maintaining a desired therapeutic drug effect over a prolonged therapy period are provided. In particular, oral dosage forms that release drug within the gastrointestinal tract at an ascending release rate over an extended time period are provided. The dosage forms may additionally comprise an immediate-release dose of drug.Type: ApplicationFiled: March 13, 2013Publication date: May 7, 2015Applicant: ALZA CORPORATIONInventors: SUNEEL K. GUPTA, DIANE R. GUINTA, CAROL A. CHRISTOPHER, SAMUEL R. SAKS, LAWRENCE G. HAMEL
-
Patent number: 9000038Abstract: Methods and devices for maintaining a desired therapeutic drug effect over a prolonged therapy period are provided. In particular, oral dosage forms that release drug within the gastrointestinal tract at an ascending release rate over an extended time period are provided. The dosage forms may additionally comprise an immediate-release dose of drug.Type: GrantFiled: March 13, 2013Date of Patent: April 7, 2015Assignee: ALZA CorporationInventors: Andrew C. Lam, Padmaja Shivanand, Atul D Ayer, Zahedeh Hatamkhany, Richard G Weyers, Suneel K. Gupta, Diane R Guinta, Carol A. Christopher, Samuel R. Saks, Lawrence G. Hamel, Jeri D. Wright
-
Patent number: 8629179Abstract: Methods and devices for maintaining a desired therapeutic drug effect over a prolonged therapy period are provided. In particular, oral dosage forms that release drug within the gastrointestinal tract at an ascending release rate over an extended time period are provided. The dosage forms may additionally comprise an immediate-release dose of drug.Type: GrantFiled: October 19, 2009Date of Patent: January 14, 2014Assignee: Alza CorporationInventors: Suneel K. Gupta, Diane R. Guinta, Carol A. Christopher, Samuel R. Saks, Lawrence G. Hamel
-
Patent number: 8163798Abstract: Methods and devices for maintaining a desired therapeutic drug effect over a prolonged therapy period are provided. In particular, oral dosage forms that release drug within the gastrointestinal tract at an ascending release rate over an extended time period are provided. The dosage forms may additionally comprise an immediate-release dose of drug.Type: GrantFiled: August 12, 2003Date of Patent: April 24, 2012Assignee: Alza CorporationInventors: Suneel K. Gupta, Diane R. Guinta, Carol A. Christopher, Samuel R. Saks, Lawrence G. Hamel
-
Publication number: 20100093796Abstract: Methods and devices for maintaining a desired therapeutic drug effect over a prolonged therapy period are provided. In particular, oral dosage forms that release drug within the gastrointestinal tract at an ascending release rate over an extended time period are provided. The dosage forms may additionally comprise an immediate-release dose of drug.Type: ApplicationFiled: October 19, 2009Publication date: April 15, 2010Inventors: Suneel K. Gupta, Diane R. Guinta, Carol A. Christopher, Samuel R. Saks, Lawrence G. Hamel
-
Publication number: 20090202631Abstract: Dosage forms and methods for providing a substantially ascending rate of release of paliperidone or risperidone are provided. The sustained release dosage forms provide therapeutically effective average steady-state plasma paliperidone or risperidone concentrations when administered once per day. This once-a-day dosing regimen results in only one peak plasma paliperidone or risperidone concentration occurrence in each 24 hour period. In addition, the peak plasma paliperidone or risperidone concentration occurs at a later time following dose administration and exhibits a lesser magnitude than the peak plasma paliperidone or risperidone concentration that occurs following administration of paliperidone or risperidone in an immediate-release dosage form.Type: ApplicationFiled: April 22, 2009Publication date: August 13, 2009Inventors: Nyomi V. Yam, Iran Reyes, Nipun Davar, Atul D. Ayer, Julie Lee, Sonya Seroff, Suneel K. Gupta, Gayatri Sathyan
-
Patent number: 7212853Abstract: An electrotransport agent delivery device (10) for delivering a therapeutic agent through intact skin, and a method of operating same, is provided. The device applies a pulsing electrotransport current wherein current pulses have a magnitude above a critical level (Ic) at which the skin is transformed into a higher electrotransport delivery efficiency (E) state. Most preferably the length of the applied current pulses is at least 5 msec and preferably at least 10 msec.Type: GrantFiled: June 7, 1996Date of Patent: May 1, 2007Assignee: Alza CorporationInventors: J. Bradley Phipps, Gary A. Lattin, Ronald P. Haak, Felix Theeuwes, Suneel K. Gupta
-
Patent number: 7136698Abstract: An electrotransport agent delivery device (10) for delivering a therapeutic agent through intact skin, and a method of operating same, is provided. The device applies a pulsing electrotransport current wherein the length of the applied current pulses is at least 5 msec and preferably at least 10 msec. Most preferably, the current pulses have a magnitude above a critical level (Ic) at which the skin is transformed into a higher electrotransport delivery efficiency (E) state.Type: GrantFiled: February 12, 2004Date of Patent: November 14, 2006Assignee: Alza CorporationInventors: J. Bradley Phipps, Gary A. Lattin, Ronald P. Haak, Felix Theeuwes, Suneel K. Gupta
-
Patent number: 7011844Abstract: Composition of matter for application to a body surface or membrane to administer fluoxetine by permeation through the body surface or membrane, the composition comprising fluoxetine to be administered, at a therapeutically effective rate, alone or in combination with a permeation enhancer or mixture. A preferred embodiment is directed to the transdermal administration of fluoxetine at reduced skin irritation levels wherein fluoxetine, preferably provided as fluoxetine acetate, is coadministered with a corticosteroid such as hydrocortisone. Also disclosed are drug delivery devices containing the fluoxetine or fluoxetine and enhancer composition and methods for the transdermal administration of the fluoxetine and fluoxetine/enhancer composition.Type: GrantFiled: November 22, 2002Date of Patent: March 14, 2006Assignee: Alza CorporationInventors: Robert M. Gale, Melinda K. Nelson, Michel J. N. Cormier, Suneel K. Gupta, Patricia S. Campbell
-
Patent number: 6930129Abstract: Methods and devices for maintaining a desired therapeutic drug effect over a prolonged therapy period are provided. In particular, oral dosage forms that release drug within the gastrointestinal tract at an ascending release rate over an extended time period are provided. The dosage forms may additionally comprise an immediate-release dose of drug.Type: GrantFiled: March 8, 2001Date of Patent: August 16, 2005Assignee: Alza CorporationInventors: Andrew C. Lam, Padmaja Shivanand, Atul D. Ayer, Zahedeh Hatamkhany, Suneel K. Gupta, Diane R. Guinta, Carol A. Christopher, Samuel R. Saks, Lawrence G. Hamel, Jeri D. Wright, Richard G. Weyers
-
Patent number: 6919373Abstract: Methods and devices for maintaining a desired therapeutic drug effect over a prolonged therapy period are provided. In particular, oral dosage forms that release drug within the gastrointestinal tract at an ascending release rate over an extended time period are provided. The dosage forms may additionally comprise an immediate-release dose of drug.Type: GrantFiled: February 19, 1999Date of Patent: July 19, 2005Assignee: Alza CorporationInventors: Andrew C. Lam, Padmaja Shivanand, Atul D. Ayer, Richard G. Weyers, Suneel K. Gupta, Diane R. Guinta, Carol A. Christopher, Samuel R. Saks, Lawrence G. Hamel, Jeri D. Wright, Zahedeh Hatamkhany
-
Publication number: 20040186417Abstract: An electrotransport agent delivery device (10) for delivering a therapeutic agent through intact skin, and a method of operating same, is provided. The device applies a pulsing electrotransport current wherein the length of the applied current pulses is at least 5 msec and preferably at least 10 msec. Most preferably, the current pulses have a magnitude above a critical level (Ic) at which the skin is transformed into a higher electrotransport delivery efficiency (E) state.Type: ApplicationFiled: February 12, 2004Publication date: September 23, 2004Inventors: J. Bradley Phipps, Gary A. Lattin, Ronald P. Haak, Felix Theeuwes, Suneel K. Gupta
-
Patent number: 6718201Abstract: An electrotransport device and method of operating same provides a pulsed DC current of specified frequency and duration which transforms the skin into a higher electrotransport delivery efficiency state.Type: GrantFiled: November 17, 1997Date of Patent: April 6, 2004Assignee: Alza CorporationInventors: J. Bradley Phipps, Gary A. Lattin, Ronald P. Haak, Felix Theeuwes, Suneel K. Gupta
-
Publication number: 20030166624Abstract: Composition of matter for application to a body surface or membrane to administer fluoxetine by permeation through the body surface or membrane, the composition comprising fluoxetine to be administered, at a therapeutically effective rate, alone or in combination with a permeation enhancer or mixture. A preferred embodiment is directed to the transdermal administration of fluoxetine at reduced skin irritation levels wherein fluoxetine, preferably provided as fluoxetine acetate, is coadministered with a corticosteroid such as hydrocortisone. Also disclosed are drug delivery devices containing the fluoxetine or fluoxetine and enhancer composition and methods for the transdermal administration of the fluoxetine and fluoxetine/enhancer composition.Type: ApplicationFiled: November 22, 2002Publication date: September 4, 2003Inventors: Robert M. Gale, Melinda K. Nelson, Michel J.N. Cormier, Suneel K. Gupta, Patricia S. Campbell
-
Patent number: 6512010Abstract: Composition of matter for application to a body surface or membrane to administer fluoxetine by permeation through the body surface or membrane, the composition comprising fluoxetine to be administered, at a therapeutically effective rate, alone or in combination with a permeation enhancer or mixture. A preferred embodiment is directed to the transdermal administration of fluoxetine at reduced skin irritation levels wherein fluoxetine, preferably provided as fluoxetine acetate, is coadministered with a corticosteroid such as hydrocortisone. Also disclosed are drug delivery devices containing the fluoxetine or fluoxetine and enhancer composition and methods for the transdermal administration of the fluoxetine and fluoxetine/enhancer composition.Type: GrantFiled: July 14, 1997Date of Patent: January 28, 2003Assignee: Alza CorporationInventors: Robert M. Gale, Melinda K. Nelson, Michel J. N. Cormier, Suneel K. Gupta, Patricia S. Campbell
-
Publication number: 20020142033Abstract: A method is disclosed for the management of dry mouth associated with the administration of an anticholinergic drug to a patient. Also, a composition and a device are disclosed comprising an anticholinergic drug administered for anticholinergic therapy.Type: ApplicationFiled: March 7, 2001Publication date: October 3, 2002Inventors: Suneel K. Gupta, Gayatri Sathyan, Samuel R. Saks
-
Publication number: 20010012847Abstract: Methods and devices for maintaining a desired therapeutic drug effect over a prolonged therapy period are provided. In particular, oral dosage forms that release drug within the gastrointestinal tract at an ascending release rate over an extended time period are provided. The dosage forms may additionally comprise an immediate-release dose of drug.Type: ApplicationFiled: March 8, 2001Publication date: August 9, 2001Inventors: Andrew C. Lam, Padmaja Shivanand, Atul D. Ayer, Zahedeh Hatamkhany, Suneel K. Gupta, Diane R. Guinta, Carol A. Christopher, Samuel R. Saks, Lawrence G. Hamel, Jeri D. Wright, Richard G. Weyers